

# Restoring life after organ failure.

eGenesis is a biotechnology company committed to using its multiplex gene editing and genome engineering platform to revolutionize the treatment of organ failure. We believe that cross-species transplantation has the potential to end waitlist mortality and remove supply as a barrier to transplant. We have built a porcine genome engineering platform using advanced gene editing to create donor animals compatible for human transplantation. Our approach focuses on three classes of genetic edits to address retroviral risk and improve immunologic as well as molecular compatibility with human recipients.



Origin	Harvard University, 2016
Headquarters	Cambridge, MA
Development Stage	Clinical
Capital Raised	\$463M
Last Financing	\$200M (3Q24)

## 18M

People globally suffer from organ failure

THE VAST MAJORITY WILL DIE WAITING FOR A TRANSPLANT



## 800K

Americans suffer from kidney failure



## 330K

Americans with acute liver decompensation



## 300K

Americans suffer end-stage heart failure

## \$80B+

Annual U.S. healthcare spend across end-stage organ disease

## Transformational Progress Since Inception

2017 —————→ 2025

- First successful production of donors with retroviral inactivation (Science, 2017)
- Produced first transgenic donor carrying 3 classes of edits addressing historical challenges that impeded cross-species transplantation (2021)
- Published landmark preclinical study (Nature, 2023) showing most extensive xenotransplant data and durable recipient survival
- Supplied EGEN-2784 kidney for world's first pig to living human kidney transplant (March 2024)
- Achieved record of 271 days dialysis independence for second patient to receive EGEN-2784 kidney (2025)

## Upcoming Milestones

2026 ————— Next 18 Months —————→

- **EGEN-2784 KIDNEY**  
Initiation of 33-patient Phase 1/2/3 study of patients with kidney failure waitlisted for transplant. Demonstration of early clinical proof of concept (6 months dialysis independence)
- **EGEN-5784 ELC LIVER**  
Completion of 20-patient Phase 1 study and demonstration of clinical proof of concept in ACLF patients
- **EGEN-4467 HEART**  
Completion of additional nonclinical studies to support IND filing and clarification of regulatory pathway for initial indication.

## Team

Experienced team of scientific, technical, and operational leaders with commitment to revolutionizing the treatment of organ failure

Mike Curtis, Ph.D. PRESIDENT & CHIEF EXECUTIVE OFFICER

Jay Barth, M.D. CHIEF MEDICAL OFFICER

Susan Low, Ph.D. HEAD OF DEVELOPMENT

Jennifer Bergheiser CHIEF BUSINESS OFFICER

Wenning Qin, Ph.D. SVP, INNOVATION

Elizabeth Roberts CHIEF PEOPLE OFFICER

# From lives on hold to future within reach.

Since 2024, we have transplanted 4 patients with our lead product for kidney failure, EGEN-2784, beginning with the first-ever transplant of a porcine kidney in a living human recipient in 2024. Our pioneering patients will continue to propel this innovation forward.



+52

DAYS

Restored kidney function



+271

DAYS

Restored kidney function



Transplanted on  
June 14, 2025

+214 Days as of 1/14/25

Restored kidney function



Transplanted on  
Nov 22, 2025

+53 Days as of 1/14/25

Restored kidney function

## Platform | Genome Modifications

### Inactivation



Pathogen Safety

Inactivation of porcine retroviruses

### Knock-outs



Elimination of Hyperacute Rejection

GGTA<sub>1</sub>  
B4GalNT2  
CMAH

### Knock-ins



Coagulation

PROCR, THBD

Inflammation/Apoptosis

HMOX1, TNFAIP3

Innate Immunity

CD47

Complement

CD46, CD55

## Pipeline

### EGEN-2784 KIDNEY

- IND clearance to conduct Phase 1/2/3 study in patients over 50 and waitlisted for transplant
- 4 transplants completed to date under Expanded Access
- Achieved record of 271 days dialysis independence

### EGEN-5784 ELC LIVER

- IND clearance to conduct Phase 1 study in patients with acute liver decompensation
- Potential to bridge patients to transplant/native recovery
- Proof of concept established in hepatectomized, decedent patient

### EGEN-4467 HEART

- Achieved 2 years graft function in baboon recipient; longest known porcine orthotopic transplant
- Exploring development pathways with FDA

RESEARCH      PRECLINICAL      IND ENABLING      CLINICAL

